



Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-022-01962-5>.
Published online 12 September 2022.

<https://doi.org/10.1038/s41591-023-02627-7>

Published online: 10 October 2023

Jamie E. Chaft , Filiz Oezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski , Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michal Seweryn, Woo Yul Byun , Katja Schulze, Alan Nicholas, Ann Johnson, Jessica Grindheim , Stephanie Hiltz, David S. Shames, Chris Rivard, Eric Toloza, Eric B. Haura, Ciaran J. McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone  & LCMC study investigators*

In the version of this article initially published, the first sentence of the Fig. 4a caption (now reading “The expression of different NK cell surface receptors was determined by scRNA-seq”) was incorrectly preceded by the text “Association between gene expression in NK cells and the percentage of viable tumor cells,” which has now been removed from the HTML and PDF versions of the article.

*A list of authors and their affiliations appears online.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.











© The Author(s) 2023

Author Correction: Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-023-02407-3>. Published online 18 July 2023.

<https://doi.org/10.1038/s41591-023-02529-8>

Published online: 16 August 2023

Sergio Serrano-Villar , Camilla Tincati, Sajan C. Raju , Johan S. Sáenz , Elena Moreno, Rafael Bargiela, Alfonso Cabello-Ubeda, Elena Sendagorta, Alina Kurz, Jose A. Perez Molina , Amparo de Benito, Johannes R. Hov , Laura Fernandez-Lopez , Alfonso Muriel , Rosa del Campo , Santiago Moreno, Marius Trøseid , Jana Seifert & Manuel Ferrer 

In the version of this article initially published, Manuel Ferrer (Instituto de Catalisis y Petroquímica (ICP), CSIC, Madrid, Spain) was shown with an incorrect affiliation, which has now been corrected in the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023